At the conclusion of this activity, participants should be better able to:

• Define clinical and laboratory features to allow for appropriate risk assessment of patients with multiple myeloma (MM)
• Review the latest clinical trial evidence on current and emerging treatments and regimens for MM
• Consider the latest evidence-based NCCN guidelines and expert recommendations for treatment of MM when formulating treatment plans for patients
• Develop approaches to individualizing therapy for MM based on individual patient health status, prognostic biomarkers, and prior treatment
• Implement strategies to improve treatment regimen adherence and supportive care for patients with MM